RU2533217C3 - Препарат, содержащий инсулин, никотинамид и аминокислоту - Google Patents

Препарат, содержащий инсулин, никотинамид и аминокислоту

Info

Publication number
RU2533217C3
RU2533217C3 RU2012100397A RU2012100397A RU2533217C3 RU 2533217 C3 RU2533217 C3 RU 2533217C3 RU 2012100397 A RU2012100397 A RU 2012100397A RU 2012100397 A RU2012100397 A RU 2012100397A RU 2533217 C3 RU2533217 C3 RU 2533217C3
Authority
RU
Russia
Prior art keywords
nicotinamide
insulin
amino acid
preparation containing
compound
Prior art date
Application number
RU2012100397A
Other languages
English (en)
Other versions
RU2012100397A (ru
RU2533217C2 (ru
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2533217(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2012100397A publication Critical patent/RU2012100397A/ru
Application granted granted Critical
Publication of RU2533217C2 publication Critical patent/RU2533217C2/ru
Publication of RU2533217C3 publication Critical patent/RU2533217C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Claims (3)

1. Инъецируемый инсулиновый препарат для снижения уровня глюкозы в крови у субъекта, содержащий инсулиновое соединение, соединение никотиновой кислоты и аргинин, в котором инсулиновое соединение представляет собой человеческий инсулин B28Asp, а соединение никотиновой кислоты представляет собой никотинамид.
2. Инъецируемый инсулиновый препарат по п. 1, в котором инсулиновое соединение присутствует в количестве 0,6 мМ.
3. Инъецируемый инсулиновый препарат по любому из пп. 1-2 для применения при лечении сахарного диабета.
RU2012100397A 2009-06-26 2010-06-25 Препарат, содержащий инсулин, никотинамид и аминокислоту RU2533217C3 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09163940.1 2009-06-26
EP09163940 2009-06-26
US22216809P 2009-07-01 2009-07-01
US61/222,168 2009-07-01
PCT/EP2010/059069 WO2010149772A1 (en) 2009-06-26 2010-06-25 Preparation comprising insulin, nicotinamide and an amino acid

Publications (3)

Publication Number Publication Date
RU2012100397A RU2012100397A (ru) 2013-08-10
RU2533217C2 RU2533217C2 (ru) 2014-11-20
RU2533217C3 true RU2533217C3 (ru) 2020-12-21

Family

ID=41351568

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012100397A RU2533217C3 (ru) 2009-06-26 2010-06-25 Препарат, содержащий инсулин, никотинамид и аминокислоту

Country Status (20)

Country Link
US (4) US8324157B2 (ru)
EP (2) EP2612677B1 (ru)
JP (2) JP5669834B2 (ru)
KR (1) KR101775000B1 (ru)
CN (2) CN102470165B (ru)
AU (1) AU2010264636B2 (ru)
BR (1) BRPI1014760B8 (ru)
CA (1) CA2764423A1 (ru)
DK (2) DK2612677T3 (ru)
ES (2) ES2440289T3 (ru)
HU (2) HUE027239T2 (ru)
IL (1) IL216520A (ru)
MX (1) MX2011012764A (ru)
NO (1) NO2017031I1 (ru)
PL (2) PL2612677T3 (ru)
PT (2) PT2612677E (ru)
RU (1) RU2533217C3 (ru)
TW (1) TWI459962B (ru)
WO (1) WO2010149772A1 (ru)
ZA (1) ZA201108942B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
BRPI1014760B8 (pt) * 2009-06-26 2021-05-25 Novo Nordisk As preparação compreendendo insulina, nicotinamida e arginina
WO2012080362A1 (en) * 2010-12-14 2012-06-21 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
WO2013186138A1 (en) * 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
BR112015011179A8 (pt) 2012-12-19 2019-10-01 Wockhardt Ltd composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
PT2950780T (pt) * 2013-02-04 2020-07-07 Sanofi Sa Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
US20150273022A1 (en) * 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
GB201613895D0 (en) 2016-08-12 2016-09-28 Arecor Ltd Novel composition
KR102482664B1 (ko) 2016-09-29 2022-12-29 아레콜 리미티드 신규한 제제
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
JP7465813B2 (ja) 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム
US20210038506A1 (en) 2018-04-04 2021-02-11 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
JPS5885815A (ja) * 1981-10-30 1983-05-23 ノボ・インダストリ・アクテイ−ゼルスカブ 安定化インシユリン製剤
DE3313386A1 (de) * 1983-04-13 1984-10-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Verfahren zur herstellung von nicht-brennbaren, thermisch isolierenden formkoerpern aus geblaehtem perlit
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
ES2072596T3 (es) * 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
RU2175556C2 (ru) * 1994-03-07 2001-11-10 Инхейл Терапьютик Системз Способы и композиции для легочной доставки инсулина
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
EP1283051B1 (en) * 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
US6734162B2 (en) * 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US20050232974A1 (en) 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
KR101487852B1 (ko) 2006-12-15 2015-01-29 티마 파운데이션 신규조성물 및 그 용도
EP2178909B1 (en) * 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
BRPI1014760B8 (pt) * 2009-06-26 2021-05-25 Novo Nordisk As preparação compreendendo insulina, nicotinamida e arginina

Also Published As

Publication number Publication date
DK2340033T3 (da) 2014-01-20
MX2011012764A (es) 2012-01-20
DK2612677T3 (en) 2015-07-27
IL216520A (en) 2017-08-31
WO2010149772A1 (en) 2010-12-29
AU2010264636B2 (en) 2013-06-27
CA2764423A1 (en) 2010-12-29
TWI459962B (zh) 2014-11-11
PL2340033T3 (pl) 2014-03-31
AU2010264636A1 (en) 2012-01-12
US20150182595A1 (en) 2015-07-02
BRPI1014760B1 (pt) 2021-04-13
JP2012530768A (ja) 2012-12-06
JP6026485B2 (ja) 2016-11-16
KR101775000B1 (ko) 2017-09-04
RU2012100397A (ru) 2013-08-10
BRPI1014760A2 (pt) 2017-07-18
US20130281364A1 (en) 2013-10-24
IL216520A0 (en) 2012-02-29
US20140206610A1 (en) 2014-07-24
JP5669834B2 (ja) 2015-02-18
PT2340033E (pt) 2014-02-04
ES2543705T3 (es) 2015-08-21
NO2017031I1 (no) 2017-07-06
EP2612677B1 (en) 2015-05-06
EP2612677A1 (en) 2013-07-10
EP2340033A1 (en) 2011-07-06
CN104667264B (zh) 2018-09-07
PT2612677E (pt) 2015-09-10
ZA201108942B (en) 2012-08-29
RU2533217C2 (ru) 2014-11-20
CN102470165B (zh) 2014-12-24
HUE027239T2 (en) 2016-10-28
CN102470165A (zh) 2012-05-23
ES2440289T3 (es) 2014-01-28
US8324157B2 (en) 2012-12-04
JP2015071608A (ja) 2015-04-16
BRPI1014760B8 (pt) 2021-05-25
HUS1700027I1 (hu) 2017-07-28
CN104667264A (zh) 2015-06-03
TW201100093A (en) 2011-01-01
BRPI1014760A8 (pt) 2018-01-09
EP2340033B1 (en) 2013-10-09
KR20120047226A (ko) 2012-05-11
PL2612677T3 (pl) 2015-10-30
US20120135920A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
RU2533217C3 (ru) Препарат, содержащий инсулин, никотинамид и аминокислоту
MX2007012102A (es) Control superior de glucosa en la sangre en tratamiento de diabetes.
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
EP2594563A3 (en) 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
EA201100097A1 (ru) Производные пиразоло[3,4]пиримидин-4-ила и их применения для лечения диабета и ожирения
MY152172A (en) Therapeutic agent for diabetes
DK2329848T3 (da) Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
BR112014010139A2 (pt) formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
WO2011089234A8 (en) Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
MY181626A (en) Treatment of diabetes mellitus by long-acting formulations of insulins
IL223434A (en) Methods in n-acetylneuraminic acid, a precursor of n-acetylneuraminic acid or their combination in the preparation of a drug for the treatment of diabetic conditions and a method for determining the status of a subject in relation to nephrotic syndrome or diabetic conditions
EA201001405A1 (ru) Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
RU2014114860A (ru) Соединения и способ для лечения сердечной недостаточности и поражения нервных клеток (варианты)
EA201100244A1 (ru) Новые кристаллические соли эпалрестата
EA201001688A1 (ru) Производные арилпиразинона стимуляторы секреции инсулина, способы их получения и их применение для лечения диабета
EP2349322A4 (en) SALT OF R - (+) - ALPHA-LIPOIC ACID STABLE AND INSOLUBLE IN WATER USEFUL FOR THE TREATMENT OF SWEET DIABETES AND ITS CO-MORBIDITIES
EA201590415A1 (ru) Производные диазепинона, применимые для лечения синдрома хрупкой х-хромосомы, болезни паркинсона или рефлюксного заболевания
WO2012047628A3 (en) Methods of managing blood sugar levels and compositions related thereto
HRP20130983T1 (hr) Derivati arilciklopropilacetamida, korisni kao aktivatori glukokinaze
WO2011152658A3 (en) Pharmaceutical composition comprising piperazine dithioctate and glimepiride
PL373543A1 (pl) Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20201221